Volume 13, Number 12—December 2007
Letter
Human Papillomavirus Vaccination Strategies
Santiago Pérez Cachafeiro*
Table
Cost-effectiveness analysis of alternative human papillomavirus vaccination strategies*
| Strategy | Discounted |
Incremental† |
||||
|---|---|---|---|---|---|---|
| Cost | QALY | Cost | QALY | ICER ($/QALY)‡ | ||
| No vaccination | $72,659,302 | 2,698,711 | – | – | – | |
| 12-y-old girls | $74,042,990 | 2,699,178 | $1,383.688 | 467 | Dominated | |
| 18-y-old women + 18–24-y-old female catch-up | $73,553,847 | 2,699,192 | $894,545 | 481 | $1,860 | |
| 15-y-old girls + 15–24-y-old female catch-up | $73,895,046 | 2,699,214 | $341,199 | 22 | $15,509 | |
| 12-y-old girls and boys | $78,707,825 | 2,699,327 | $4,812,779 | 113 | Dominated | |
| 12-y-old girls + 12–24-y-old female catch-up | $74,815,667 | 2,699,343 | $920,621 | 129 | $7,137 | |
| 18-y-old women and men + 18–24-y-old female and male catch-up | $77,535,383 | 2,699,385 | $2,719,716 | 42 | $64,755 | |
| 15-y-old girls and boys + 15–24-y-old female and male catch-up | $78,455,750 | 2,699,404 | $920,367 | 19 | $48,440 | |
| 12-y-old girls and boys + 12–24-y-old female catch-up | $79,746,357 | 2,699,461 | $1,290,607 | 57 | $22,642 | |
| 12-y-old girls and boys + 12–24-y-old female and male catch-up | $81,761,210 | 2,699,506 | $2,014,853 | 45 | $44,775 | |
*QALY, quality-adjusted life year; ICER, incremental cost-effectiveness ratio; $, US dollars.
†Based on discounted costs reported by Elbasha et al. (1).
‡Compared with the preceding nondominated strategy. Strategy A is dominated if there exists another strategy, B, that is more effective and less costly than strategy A.
